Clinical Trials

Multiple clinical trials evaluate the therapeutic utility of varenicline across indications such as vaping cessation, dry eye disease, and cannabis use disorder. Spanning Early Phase 1, Phase 1, and Phase 2, these studies are supported by academic institutions and pharmaceutical companies, including the Mayo Clinic, the Medical University of South Carolina, Ji Xing Pharmaceuticals, and Oyster Point Pharma. Trial recruitment statuses encompass both completed investigations evaluating safety, pharmacokinetics, and efficacy, as well as withdrawn protocols.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04317300 Withdrawn
Vaping
Mayo Clinic
 2023-02-01 Early Phase 1
NCT05576415 Completed
Dry Eye Disease
Ji Xing Pharmaceuticals (Shanghai) Co. Ltd.|Oyster Point Pharma Inc.
 2022-12-07 Phase 1
NCT03980561 Completed
Cannabis Use Disorder
Medical University of South Carolina
 2020-01-31 Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Varenicline product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Varenicline selectively binds to neuronal α4β2 nicotinic acetylcholine receptors and 5-HT3 serotonin receptors, blocking downstream cholinergic channel activation and modulating central neurotransmitter release. This regulation of receptor activity suppresses craving pathways and stimulates lacrimal tissue secretion, providing the mechanistic rationale for its clinical evaluation in vaping cessation, cannabis use disorder, and dry eye disease.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.